GCS-100LE Clinical Trial Program Gets Additional Cancer Indication

GlycoGenesys, a biotechnology company focused on carbohydrate-based drug development, announced a new indication, chronic lymphocytic leukemia (CLL), for its cancer clinical trial program for GCS-100LE.

The addition of CLL to its clinical trial program positions GlycoGenesys to pursue approval in two indications for unmet medical needs in cancer and starts the international clinical and regulatory program for GCS-100LE.

In recognition of the expanded clinical program, the company announced its commitment to establishing a strategic alliance in 2005. It also provided a brief update on its ongoing Phase I dose-escalation trial, while setting forth its 2005 goals including its multiple myeloma clinical trial program planned for early 2005.